CTIS2024-516032-10-00招募中1 期
A study to investigate the mechanistic effects of dapagliflozin alone or in combination with balcinrenone, compared to balcinrenone and placebo on body fluid and electrolyte handling and energy metabolism in participants over 50 years of age with chronic kidney disease (DapaBalci-Leap) - CT114-2022-01
Winicker-Norimed Medizinische Forschung GmbH0 个研究点目标入组 150 人开始时间: 2024年7月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age: Male and female patients over 50 years old Type of Participant and Disease Characteristics, Diagnosis of chronic kidney disease, with eGFR =30 and =60 mL/min/1.73m2, A) Germany: Serum/ plasma K+ levels = 3.5 and < 5.0 mmol/L OR within normal laboratory ranges when these are provided, within 2 weeks prior to randomization B) France: Serum/ plasma K+ levels = 3.5 and < 5.0 mmol/L within 2 weeks prior to randomization, Serum/plasma Na+ levels within normal reference values within 2 weeks prior to randomization, If participants have type 2 diabetes mellitus, treatment with metformin, sulphonylureas, DPP4 inhibitors or any combinations of these agents with or without insulin would be accepted but is not mandatory. If used, stable dose of metformin, sulphonylureas, or DPP4 inhibitors or their combination as anti-diabetic therapy for the 12 weeks prior to randomization is required, No changes in background treatment for at least 3 weeks prior to randomization, Body mass index less than 40 kg/m2, Negative pregnancy test (urine or serum) for female subjects of childbearing potential and willingness to use a highly effective birth control (see Appendix 4) if of childbearing potential, Willingness to participate and ability to provide signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
排除标准
- •Diagnosis of type 1 diabetes mellitus, Significant hepatic disease, including hepatitis and/or liver cirrhosis (Child-Pugh class A-C), or AST or ALT > 2 × ULN (upper limit of normal); or total bilirubin levels (TBL) > 2 × ULN; or serum albumin levels < 3.5 g/dL, Medical conditions associated with development of hyperkalemia (Addison's disease), Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within 3 months prior to screening, A) Germany: Hemoglobin levels below 8.5 g/dL or over 15 g/dL OR over the normal laboratory ranges, when these are provided B) France: Hemoglobin levels below 8.5 g/dL or over 15 g/dL, A) Germany: Patients who have received an organ transplant at any time or bone marrow transplant in the previous 10 years B) France: Patients who have received an organ or bone marrow transplant, HIV infection, Active cancer, history of bladder cancer, Patients who have had major surgery in the 3 months prior to screening, Patients with muscular dystrophies, Patients who have severe comorbid conditions likely to compromise survival or study participation, Uncontrolled type 2 diabetes mellitus with HbA1C > 10.5% in the most recent medical records, Pregnant and breast-feeding women, Medical treatment with either a mineralocorticoid receptor antagonist (MRA) or a sodium-glucose co-transporter-2 inhibitor (SGLT2i) within 3 months prior to screening, Medical treatment with potassium binders, Medical treatment with strong or moderate CYP3A4 inducers or inhibitors, Prior serious hypersensitivity reaction to dapagliflozin (Forxiga®), balcinrenone or to any of their excipients, Treatment with cytotoxic therapy, immunosuppressive therapy or other immunotherapy within 6 months prior to screening, Unwillingness or other inability to cooperate, For patients undergoing MRI scans, presence of implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants), iron-based tattoos, any other pieces of metal or devices that are not MR-safe anywhere in the body, Participants with type 2 diabetes mellitus treated with insulin if insulin dosing (intermediate, long-acting, premixed insulin, basal bolus insulin) was not stable in the 12 weeks prior to randomization as judged by the Investigator, Patients with systolic blood pressure levels <100 mmHg at the time of enrolment, Patients with congestive heart failure NYHA stage IV or hospitalized for decompensation of heart failure in the 3 months prior to screening, History of any life-threatening cardiac arrhythmias, or uncontrolled ventricular rate in participants with atrial fibrillation or atrial flutter, Acute coronary syndrome and/or percutaneous cardiac interventions within 3 months prior to screening, Unstable or rapidly progressing renal disease, Chronic cystitis and recurrent genital or urinary tract infections
研究者
相似试验
已完成
不适用
An exploratory study for examining the effects of PE on relaxation and stress in healthy adults: A Randomized, Double-blind, Placebo-controlled, Crossover Study.oneJPRN-UMIN000024808Otsuka Pharmaceutical Co., Ltd.24
招募中
不适用
A study investigating the effect of Java ginger extract in patients with refractory leg neuropathic paiueropathic painpain,D009437JPRN-jRCTs041210100shida Takahiro10
招募中
不适用
Study of investigating the mechanism of action of azacitidine in patients with myelodysplastic syndrome/acute myeloid leukemia with myelodysplasia-related changes by single cell RNA sequencemyelodysplastic syndrome,acute myeloid leukemia with myelodysplasia-related changesJPRN-UMIN000042515The University of Tokyo17
尚未招募
不适用
A study to investigate appetite in older adults residing in nursing homes.ANL-OMON22468Danone Nutricia Research45
已完成
不适用
An exploratory study investigating the effect of adding an appetite stimulant to an ONS on appetite-related outcomes in nursing home residents and in older adults in need of additional nutritional supportNL-OMON52167utricia17